Comparison of the Subjective Well-being and Tolerability of Quetiapine XR to Risperidone
Status:
Completed
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
The trial is designed to assess the long term subjective well-being in schizophrenic
outpatients treated with quetiapine XR (extended release) or oral risperidone at flexible
dose in a naturalistic setting over a period of one year. Secondary outcome measures have
been selected for helping in the differentiation of the compared atypical antipsychotics. The
primary objective of this study is to demonstrate the non-inferiority of quetiapine XR to
risperidone assessed at month 6 in terms of responder rate using the self-report instrument
SWN-K